Pozniak, Anton <br/><br/>
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.  [electronic resource] 

 -  HIV clinical trials  07 2017 
 - 141-148 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>1945-5771 
<br/><br/><label>Standard No.: </label>10.1080/15284336.2017.1338844  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiretroviral Therapy, Highly Active--adverse effects<br/>Cobicistat--administration & dosage<br/>Drug Combinations<br/>Drug Substitution<br/>Emtricitabine--administration & dosage<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--drug effects<br/>Humans<br/>Male<br/>Patient Reported Outcome Measures<br/>Quinolones--administration & dosage<br/>Tablets<br/>Tenofovir--administration & dosage<br/>Time Factors<br/>Treatment Outcome